C. Barbara
About
C. Barbara is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery.
According to data from OpenAlex, C. Barbara has authored 32 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 4 papers in Surgery. Recurrent topics in C. Barbara's work include Colorectal Cancer Treatments and Studies (22 papers), Cancer Treatment and Pharmacology (13 papers) and Lung Cancer Treatments and Mutations (6 papers). C. Barbara is often cited by papers focused on Colorectal Cancer Treatments and Studies (22 papers), Cancer Treatment and Pharmacology (13 papers) and Lung Cancer Treatments and Mutations (6 papers). C. Barbara collaborates with scholars based in Italy, Argentina and Greece. C. Barbara's co-authors include Alfredo Falcone, Giacomo Allegrini, Gianluca Masi, Cristina Granetto, Lucio Crinò, M. Andreuccetti, I. Brunetti, Silvana Chiara, S. Vitello and V. Picone and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and British Journal of Cancer.
In The Last Decade
C. Barbara
32 papers receiving 1.5k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| C. Barbara Italy | 15 | 1.2k | 532 | 454 | 334 | 206 | 32 | 1.5k | ||
| M. Andreuccetti Italy | 14 | 1.5k 1.2× | 841 1.6× | 563 1.2× | 374 1.1× | 209 1.0× | 28 | 1.8k | ||
| May Mabro France | 19 | 1.3k 1.0× | 403 0.8× | 520 1.1× | 288 0.9× | 152 0.7× | 54 | 1.5k | ||
| Karen Rittweger United States | 14 | 967 0.8× | 173 0.3× | 367 0.8× | 280 0.8× | 134 0.7× | 17 | 1.3k | ||
| Jenny F. Seligmann United Kingdom | 14 | 1.2k 1.0× | 277 0.5× | 440 1.0× | 329 1.0× | 223 1.1× | 61 | 1.6k | ||
| Toru Yasutake Japan | 23 | 685 0.6× | 265 0.5× | 379 0.8× | 663 2.0× | 391 1.9× | 112 | 1.5k | ||
| G. Gruia France | 5 | 2.4k 2.0× | 903 1.7× | 713 1.6× | 553 1.7× | 566 2.7× | 7 | 2.8k | ||
| Lucille Leong United States | 23 | 691 0.6× | 169 0.3× | 265 0.6× | 270 0.8× | 502 2.4× | 74 | 1.6k | ||
| Nicoletta Pirotta United States | 10 | 2.2k 1.8× | 844 1.6× | 797 1.8× | 624 1.9× | 651 3.2× | 16 | 2.8k | ||
| Mitsukuni Suenaga Japan | 21 | 1.1k 0.9× | 147 0.3× | 533 1.2× | 240 0.7× | 271 1.3× | 149 | 1.5k | ||
| W P Tong United States | 19 | 1.1k 0.9× | 193 0.4× | 421 0.9× | 339 1.0× | 506 2.5× | 31 | 1.8k |
Countries citing papers authored by C. Barbara
Since
Specialization
Citations
This map shows the geographic impact of C. Barbara's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Barbara with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Barbara more than expected).
Fields of papers citing papers by C. Barbara
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by C. Barbara. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Barbara. The network helps show where C. Barbara may publish in the future.
Co-authorship network of co-authors of C. Barbara
This figure shows the co-authorship network connecting the top 25 collaborators of C. Barbara. A scholar is included among the top collaborators of C. Barbara based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Barbara. C. Barbara is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Salvatore, Lisa, Maria Bensi, Filippo Pietrantonio, et al.. (2019). Phase II study of preoperative (PREOP) chemoradiotherapy (CTRT) plus avelumab (AVE) in patients (PTS) with locally advanced rectal cancer (LARC): The AVANA Study. Annals of Oncology. 30. v249–v249.
2.
Marmorino, Federica, Lisa Salvatore, C. Barbara, et al.. (2017). Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer. British Journal of Cancer. 116(3). 318–323.
3.
Cremolini, Chiara, Fotios Loupakis, Gianluca Masi, et al.. (2016). FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials. Annals of Oncology. 27(5). 843–849.
4.
Masi, Gianluca, Lisa Salvatore, Luca Boni, et al.. (2015). Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial. Annals of Oncology. 26(4). 724–730.
5.
Cremolini, Chiara, Fotios Loupakis, Daniele Rossini, et al.. (2014). Folfoxiri with or Without Bevacizumab (Bev) As First-Line Treatment of Metastatic Colorectal Cancer (Mcrc): a Propensity Score-Based Analysis. Annals of Oncology. 25. iv175–iv175.
6.
Cappuzzo, Federico, Andrea Sacconi, Lorenza Landi, et al.. (2013). MicroRNA Signature in Metastatic Colorectal Cancer Patients Treated With Anti-EGFR Monoclonal Antibodies. Clinical Colorectal Cancer. 13(1). 37–45.e4.
7.
Petrelli, Fausto, Sílvia Colombo, C. Barbara, et al.. (2011). A Rare Case of Metastatic Pancreatic Hepatoid Carcinoma Treated with Sorafenib. Journal of Gastrointestinal Cancer. 43(1). 97–102.
8.
Petrelli, Fausto, Mary Cabiddu, C. Barbara, & Sandro Barni. (2011). A patient presenting nasal septum perforation during bevacizumab-containing chemotherapy for advanced breast cancer. Breast Cancer. 18(3). 226–230.
9.
Re, Marzia Del, Fotios Loupakis, Angela Michelucci, et al.. (2011). Prediction of fluoropyrimidine toxicities by screening DPYD genetic variants.. Journal of Clinical Oncology. 29(15_suppl). 10524–10524.
10.
Maio, Ermelinda De, Carmelo Tibaldi, Armida D’Incecco, et al.. (2010). Consequences of targeted treatments for second-line therapy. Annals of Oncology. 21. vii234–vii240.
11.
Falcone, Alfredo, Sergio Ricci, I. Brunetti, et al.. (2007). Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) As First-Line Treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord Ovest. Journal of Clinical Oncology. 25(13). 1670–1676.
12.
Bocci, Guido, et al.. (2006). A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity. Clinical Pharmacology & Therapeutics. 80(4). 384–395.
13.
Barbara, C., Paola Orlandi, Guido Bocci, et al.. (2006). In vitro and in vivo antitumour effects of novel, orally active bile acid-conjugated platinum complexes on rat hepatoma. European Journal of Pharmacology. 549(1-3). 27–34.
14.
Masi, Gianluca, Lorenzo Marcucci, Fotios Loupakis, et al.. (2006). First-line 5-fluorouracil/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) does not impair the feasibility and the activity of second line treatments in metastatic colorectal cancer. Annals of Oncology. 17(8). 1249–1254.
15.
Orlandi, Paola, C. Barbara, Guido Bocci, et al.. (2005). Idarubicin and Idarubicinol Effects on Breast Cancer Multicellular Spheroids. Journal of Chemotherapy. 17(6). 663–667.
16.
Paolo, Antonello Di, et al.. (2002). PHARMACOKINETICS OF AZITHROMYCIN IN LUNG TISSUE, BRONCHIAL WASHING, AND PLASMA IN PATIENTS GIVEN MULTIPLE ORAL DOSES OF 500 AND 1000 MG DAILY. Pharmacological Research. 46(6). 545–550.
17.
Masi, Gianluca, Antonello Di Paolo, Giacomo Allegrini, et al.. (2001). A phase I and pharmacokinetic study of irinotecan given as a 7 days continuous infusion in metastatic colorectal cancer patients pretreated with 5-FU or raltitrexed. European Journal of Cancer. 37. S294–S295.
18.
Trípodi, Valeria, et al.. (2001). Analysis of immunosuppressive drugs and their pharmaceuticals by micellar electrokinetic chromatography. Chromatographia. 54(1-2). 93–98.
19.
Innocenti, Federico, Claudio Favre, Mariacristina Menconi, et al.. (2000). Variable Correlation Between 6-Mercaptopurine Metabolites in Erythrocytes and Hematologic Toxicity: Implications for Drug Monitoring in Children With Acute Lymphoblastic Leukemia. Therapeutic Drug Monitoring. 22(4). 375–382.
20.
Fogli, Stefano, Romano Danesi, Federico Innocenti, et al.. (1999). An Improved HPLC Method for Therapeutic Drug Monitoring of Daunorubicin, Idarubicin, Doxorubicin, Epirubicin, and Their 13-Dihydro Metabolites in Human Plasma. Therapeutic Drug Monitoring. 21(3). 367–367.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by M. Andreuccetti Breakdown of academic impact, for papers by May Mabro Breakdown of academic impact, for papers by Karen Rittweger Breakdown of academic impact, for papers by Jenny F. Seligmann Breakdown of academic impact, for papers by Toru Yasutake Breakdown of academic impact, for papers by G. Gruia Breakdown of academic impact, for papers by Lucille Leong Breakdown of academic impact, for papers by Nicoletta Pirotta Breakdown of academic impact, for papers by Mitsukuni Suenaga Breakdown of academic impact, for papers by W P Tong